Rezubio Announces FDA and NMPA IND Clearances and First Cohort Dosing of RZ-520, a ...

Rezubio Pharmaceuticals has received IND clearances from the US FDA and Chinese NMPA and completed dosing of the first cohort in its Phase 1 trial for RZ-520, an inhaled therapy for chronic respiratory diseases developed on its proprietary MADD platform.

This Wire brief sits within Fusion42's coverage of Biotech.